Why the study?
High-risk features such as female gender, diabetes mellitus, multivessel disease, total occlusions, long lesions, and small vessels remain challenging subgroups in contemporary PCI requiring further evaluation with ultrathin strut biodegradable polymer-coated SES.
Does the use of ultrathin strut biodegradable polymer-coated sirolimus-eluting stents improve 1-year clinical outcomes in high-risk real-world patients with coronary artery disease?
Does the use of ultrathin strut biodegradable polymer-coated sirolimus-eluting stents improve 1-year clinical outcomes in high-risk real-world patients with coronary artery disease?
Answers are grounded in this paper and cite their sources.
Ultrathin strut biodegradable polymer-coated sirolimus-eluting stents demonstrate low rates of target lesion failure and stent thrombosis at one year in high-risk real-world patients.
Background Despite significant evolution in stent technology, female gender, and patients with diabetes mellitus, multivessel disease, total occlusions, long lesions, and small vessels represent the "Achilles' heel" of contemporary percutaneous coronary intervention (PCI). We performed a pooled analysis of high-risk subgroup on patient-level data from the T-Flex registry (1,203 patients) and a real-world Indian registry (1,269 patients), with the aim of assessing one-year safety and clinical performance of ultrathin strut biodegradable polymer-coated Supra family of sirolimus-eluting stents (SES) (Sahajanand Medical Technologies Limited, Surat, India) in the real-world, all-comer population. Method We pooled the following high-risk subgroups data from two all-comer registries: female gender (n=678), diabetes mellitus (n=852), multivessel disease (n=406), total occlusions (n=420), long lesions (≥28 mm) (n=1241), and small vessels (≤2.5 mm) (n=726). Both the registries included patients with coronary artery disease who underwent implantation of at least one SES belonging to the Supra family of stents from May 2016 until March 2018, irrespective of lesion complexity and comorbidities. The primary endpoint was the inci-dence of target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revas-cularization by percutaneous or surgical methods up to one year. The safety endpoint was stent thrombosis. Results According to prespecified high-risk subgroups, one-year rates of TLF and overall stent thrombosis, respectively, were as follows: female gender (4.9% and 0.6%), diabetes mellitus (6.9% and 1.0%), multivessel disease (6.4% and 0.8%), total occlusions (5.2% and 0.5%), long lesions (≥28 mm) (6.6% and 0.8%), and small vessels (≤2.5 mm) (6.1% and 1.3%). Conclusion This present pooled analysis demonstrated the one-year safety and clinical performance of ultrathin strut biodegradable polymer-coated Supra family of SES in a real-world, all-comer population, with considerably low rates of TLF and stent thrombosis.
No takes yet. Share an insight, caveat, or question.
Pothineni et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: